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Abstract
Our knowledge of the variety and abundances of RNA base modifications is rapidly increas-
ing. Modified bases have critical roles in tRNAs, rRNAs, translation, splicing, RNA interfer-
ence, and other RNA processes, and are now increasingly detected in all types of
transcripts. Can new biological principles associated with this diversity of RNA modifica-
tions, particularly in mRNAs and long non-coding RNAs, be identified? This review will
explore this question by focusing primarily on adenosine to inosine (A-to-I) RNA editing by
the adenine deaminase acting on RNA (ADAR) enzymes that have been intensively studied
for the past 20 years and have a wide range of effects. Over 100 million adenosine to ino-
sine editing sites have been identified in the human transcriptome, mostly in embedded Alu
sequences that form potentially innate immune-stimulating dsRNA hairpins in transcripts.
Recent research has demonstrated that inosine in the epitranscriptome and ADAR1 protein
establish innate immune tolerance for host dsRNA formed by endogenous sequences.
Innate immune sensors that detect viral nucleic acids are among the readers of epitranscrip-
tome RNA modifications, though this does preclude a wide range of other modification
effects.
Introduction
Conventional RNA-Seq is unable to address how much RNAmodification occurs in mRNA
and noncoding RNAs. Reverse transcriptases used in cDNA synthesis have evolved tolerances
for diverse types of base modification in the RNA template; amazingly, they can even make
cDNA copies of highly modified sections of tRNAs and rRNAs [1]. This evolutionary feature
of reverse transcriptases is likely to reflect the presence of a range of modified bases in RNAs
https://www.broadcastify.com/listen/feed/2822 but it also means that standard protocols for
cDNA synthesis and sequence analysis do not reveal most modified bases. Until now, identifi-
cations of modified bases in mRNAs have relied mainly on mass spectrometry or antibodies
specific for the modified base, or on the detection of different responses of the modified base
versus the normal base to some chemical modification ([2] and references therein). However,
there have been some recent developments to improve the detection of certain modifications
[3].
RNA base modifications—in particular, base methylations in mRNAs and noncoding
RNAs—have been described as the “epitranscriptome” [4–6], suggesting that effects of modi-
fied RNA bases also involve reader, writer, and eraser proteins. Base modification enzymes
have switched between DNA and RNA substrates in evolution. Studies on adenosine to inosine
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(A-to-I) editing by adenine deaminases acting on RNA (ADARs) now show that innate
immune nucleic acid sensors are one set of readers of modified bases in RNA [7]. It is now
clear that modified bases in either DNA or RNA aid innate immune sensors in discriminating
between host and viral RNAs.
N6-methyladenosine (m6A) Writers, Readers, and Erasers in
mRNAs and Noncoding RNAs
The emerging roles of N6-methyladenosine (m6A) have received a lot of recent attention. m6A
does not change base-pairing preferences of RNA and cannot recode open reading frames. It
has been found in approximately 7,000 mRNAs with an enrichment around the stop codon
and in the 30UTR regions of transcripts [8]. This is the RNA base modification that has been
characterised in the terms of the epitranscriptome model, as the addition and removal of a
methyl group is reminiscent of DNA methylation and epigenetics. The modification is intro-
duced by IME4 in Drosophila and by the METTL3 and METTL14 proteins in vertebrates; YTH
and hnRNP C proteins bind to RNAs containing the m6A base as readers, and the fat mass and
obesity-associated gene (FTO) and ALKBH5 enzymes are erasers able to demethylate the m6A
(for review, see [9]). Drosophila Ime4mutants fail to induce meiosis and mouseMettl3mutant
embryonic stem (ES) cells fail to differentiate. Pluripotency transcripts that normally have m6A
accumulate to higher levels when they are unmodified in theMettl3mutant ES cells and do not
decrease to allow differentiation [10]. A possible explanation for this is that theMettl3 pheno-
type is due to an altered balance between transcript production and turnover; the reader pro-
teins YTH and hnRNP C may facilitate the turnover of subsets of m6A-containing transcripts.
Although m5C modification at CpG islands in DNA is the canonical example of an epige-
netic modification, studies on m5C in RNA are still at an early stage. Several different methods
have been used to identify m5C positions in RNAs, with little overlap between these sites found
within either mRNA or ncRNA (for review, [11]). The biological role of m5C in mRNA and
ncRNA is largely unknown, and proteins binding m5C in RNA have not yet been identified.
Diverse Roles of A-to-I RNA Editing by ADARs
Studies on ADAR RNA editing can also be interpreted in relation to the epitranscriptome
model. The earliest work on ADARs focused on their recoding of codons in open reading
frames but recent findings on ADAR1 have uncovered effects normally associated with other
types of base modification.
The ADAR RNA-editing enzymes convert adenosine (A) to inosine (I) by hydrolytic deami-
nation of adenosine bases within double-stranded (ds)RNA [12]. Individual adenosine bases
are edited in pre-mRNAs when exons form short RNA hairpin structures, usually with nearby
introns. Editing within exons can result in recoding of open reading frames because inosine is
read as guanosine by the translational machinery [13]. Inosine prefers to form base pairs with
cytosine, so ADAR RNA editing sites are easily identified since A in the genomic sequence
appears as G in cDNA sequences [14]. ADARs primarily recognize duplex RNA that is in the
A-form; they prefer certain bases beside the edited A but do not recognize a strong consensus
sequence [15]. Studies on site-specific RNA editing have focused on ADAR2 which is enriched
in the brain and is responsible for editing the Glutamine to Arginine Q/R site in the Gria2 tran-
script and many of the other specific sites in CNS transcripts [16]. Editing the Gria2 Q/R site
appears to be the main function of ADAR2 as Adar2mutant mice, which die from seizures
three weeks after birth, can be rescued by knocking-in the edited isoform Gria2 R [17].
The ADAR proteins are comprised of two or three dsRNA binding domains (dsRBDs) at
the amino terminus and a catalytic adenosine deaminase domain at the carboxyl terminus.
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Mammals have five related ADAR proteins (Fig 1). ADAR1 and ADAR2 are enzymatically
active (for review, [18]) but enzymatic activity has never been demonstrated for the brain-spe-
cific ADAR3 protein, even though it closely resembles ADAR2 [19]. The more divergent testis-
specific adenine deaminase domain-contain proteins (ADAD1 and ADAD2) lack key catalytic
residues but are still evolutionarily conserved, presumably acting as dsRNA-binding proteins
[20,21]. Conservation of deaminase domain fold structure and key active site residues show
that the ADARs are members of the cytidine deaminase protein family (CDAs); different cyto-
sine deaminases edit cytosine to uracil in RNA or DNA or both [22].
Whereas ADAR2 has a major role in site-specific editing, ADAR1 performs “promiscuous”
editing of transcripts encoding repetitive elements (for review, [23]). This is reflected in their
different biological roles. ADAR1 is more stable than ADAR2 and thus was the first to be iden-
tified and purified [24,25]. Unlike recombinant ADAR2, purified endogenous ADAR2 is not
stable [26]. It is post-translationally regulated by phosphorylation, proline isomerization, and
ubiquitination [27]. The first distinctive features of ADAR1 were its wider tissue distribution
and the higher levels of expression in most tissues than ADAR2. Another distinctive feature of
ADAR1 is that it expresses two different isoforms—a constitutive and predominantly nuclear
Fig 1. A schematic representation of the ADAR and related ADAD proteins present in humans. All proteins have dsRNA binding domains (grey box)
and a C-terminal deaminase domain (purple box). A nuclear localization sequence (NLS) is marked in red, whereas the nuclear export signal (NES) present
in ADAR1 is marked in green. Z-DNA binding domains are indicated by an orange box in ADAR1. A region enriched in arginine/lysine residues, R domain is
present in ADAR3 (blue box). The number of amino acids is indicated on the right.
doi:10.1371/journal.pgen.1005687.g001
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110 kDa isoform and a larger interferon-induced and mainly cytoplasmic 150 kDa isoform
[28–30]. Both ADAR1 isoforms shuttle between cytoplasm and nucleus [31]. One area of con-
troversy is whether ADAR1 is pro- or antiviral (for review, [32] and references therein). There
is evidence for both points of view; however, viruses sometimes hijack the cell’s defence system
so that antiviral proteins appear to have a pro-viral role [33].
Transgenic Adar1-/- mice die at day E12.5 with defects in haematopoiesis and generalized
induction of interferon and the interferon-stimulated gene (ISG) transcripts [34–36]. It was
presumed that the Adar1mutant phenotype would be due to loss of a site-specific editing event
that alters a protein or microRNA required for stem cell maintenance or blood system develop-
ment [36]. An intense search ensued to identify ADAR1-edited transcript(s) or noncoding
RNAs. This approach proved unsuccessful and for over ten years the molecular cause of the
mortality in the Adar1-/- mice remained elusive.
Innate Immune Sensor Proteins As Readers of Inosine in dsRNA
Eventually, a different genetic approach was undertaken to rescue the Adar1mutant mice [7],
based on the idea that the mutant defect is caused by aberrant activation of the innate immune
system by cellular dsRNA and not due to a defect in site-specific editing. ADAR1 is primarily
responsible for promiscuous editing of transcripts encoding repetitive elements such as short
interspersed nuclear elements (SINEs) which, in humans, are Alu elements [37,38]. On aver-
age, human pre-mRNAs contain about ten embedded Alu elements. Alu elements can readily
form RNA duplexes that are promiscuously edited at low levels when they lie within one or
two kilobases of each other in inverted orientations; this accounts for the majority of all identi-
fied RNA editing events in human transcripts [38]. Some transcripts have Alu duplexes in their
30 UTRs that can reach the cytoplasm [39], where dsRNA can activate the innate immune
responses.
Viral dsRNA in the cytoplasm is detected by the innate immune sensor proteins Retinoic
acid-Inducible Gene 1 (RIG-I) and Melanoma Differentiation-Associated protein 5 (MDA5)
(review in [40]). These RIG-I-like (RLR), innate immune sensors bind dsRNA with RNA heli-
case domains; they do not unwind dsRNA, as they lack the required structure elements, but
instead they scan dsRNA by using ATPase activity to translocate smoothly along it or to disas-
sociate and re-associate [41–43]. The key adapter protein mediating antiviral responses and
interferon induction by dsRNA through the RLR pathway is the mitochondrial antiviral-signal-
ling protein (MAVS), also known as VISA, IPS-1, and CARDIF (for review, [44]). Double
homozygous Adar1;Mavsmice survive to birth, and ISG transcripts that were aberrantly acti-
vated in the Adar1mutant embryos returned to normal in the double mutant embryos (Fig 2)
[7]. Therefore, the Adar1mutant defect in these mice is due to an aberrant innate immune
response, and ADAR1 is not required primarily for development of the embryonic haemato-
poietic system [34–36] nor is it essential for the function of DICER in early development [45]
as, otherwise, the Adar1;Mavsmice would not survive to birth [46]. However, ADAR1 may
affect these processes indirectly.
Restoring expression of either ADAR1 or an ADAR2 mutant that localizes to the cyto-
plasm in stably transfected Adar1; P53MEF cells reduces the level of transcription of ISGs,
whereas catalytically inactive ADAR1 does this to an observable but considerably lower
extent [7]. Thus, the Adar1mutant phenotype appears to be mainly due to loss of inosine in
RNA, withMavs rescuing as it blocks the aberrantly activated signalling from both of the
RLR dsRNA sensors. The effect of inosine-containing dsRNA is dominant; dsRNA oligonu-
cleotide-containing inosine can bind to RIGI and MDA5, thus inhibiting the innate immune
response [47].
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Part of the ADAR1 effect is due to an editing-independent function. A recent study demon-
strated that knocking-in the Adar1E861A catalytically inactive mutation in mice gives an embry-
onic phenotype that is similar to, but not as severe as, the complete null [48]. The Adar1E861A
catalytically inactive mutant embryos die two days later (E14.5 versus E12.5) [48], and a double
mutant that eliminates just one of the RLR sensors, MDA5 (Ifih1-/-), rescues the Adar1E861A
mutant but not Adar1 null mutant embryos [7]. This implies that the presence of the inactive
Adar1E861A protein partially rescues the Adar1 null mutant phenotype in the whole embryo,
presumably because it still binds the most critical immune-inducing RNAs. Enzymes that
introduce epigenetic modifications in chromatin also show partial rescues by catalytically-inac-
tive mutants [49,50]. Maintaining the structure of a particular protein complex on the correct
nucleic acid partially substitutes for lack of the epigenetic modification. ADARs bind to more
dsRNAs than they edit, and the inosine base in a substrate does not necessarily change the
binding affinity [51,52]. For epitranscriptome RNA base modifications in general, persistent
binding of writer enzymes and interactions with other proteins could contribute in parallel
with the base modification itself.
While it is tempting to associate the ADAR1 editing-independent activity with Alu or SINE
RNAs, this remains an entirely open question. ADAR proteins are not abundant, and many
adenosines in Alu RNA hairpins are edited at efficiencies below 1%. The editing-independent
ADAR1 effect may involve particular immune-inducing ADAR target RNAs present in both
mice and humans. ADAR1 tightly binds many of the conserved pre-mRNA structures that are
site-specifically edited by ADAR2; some such RNA structures are entirely in exons or UTR
regions and might reach the cytoplasm to affect innate immune sensors. The inactive ADARs,
the brain specific ADAR3, and the two testis-specific ADAR-related ADAD proteins present in
the genome may also bind particular RNAs that are tissue-specific (for review [23]).
Fig 2. A model for the role of ADAR1 in innate immunity. (A) DsRNA that is generated during transcription is edited by ADARs. The dsRNA contain
inosine that can bind to the RLRs, MDA5 and RIG-I, in the cytoplasm and inhibit their activation. (B) During a viral infection, or if ADAR1 is inactive, unedited
dsRNA is present in the cytoplasm. This dsRNA binds to MDA5 and RIG-I, activating MAVS which, in turn, leads to the phosphorylation of IRF3 and its
translocation into the nucleus and induces the type 1 interferon response. (C) The ADAR1 isoform p150 is induced by interferon late in the response. This
isoform is predominantly cytoplasmic and it edits all dsRNA either of viral or cellular origin. This generates inosine containing dsRNA that can inhibit the RLR
receptors, thus turning off the interferon response as the transcription factor IRF9 is unable to continue to transcribe the ISGs.
doi:10.1371/journal.pgen.1005687.g002
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The importance of epitranscriptome base modification for innate immune regulation is well
illustrated by Aicardi-Goutières syndrome (AGS), which is caused by mutations in ADAR1
[53]. AGS is a fatal childhood congenital encephalopathy with interferon overexpression, and
children with ADAR1 mutations also present with childhood dystonia due to bilateral striatal
neurodegeneration, again with interferon expression. One could envisage that when an AGS
child with ADAR1mutations catches a transient viral infection, reduced ADAR1 dosage or
activity leads to unedited cellular RNAs in the cytoplasm binding to RLRs, stimulating an
innate immune response (Fig 2). After 12 hours, ADAR1p150, which is mainly cytoplasmic, is
induced by interferon. It should edit all RNAs in the cytoplasm, thus turning off the innate
immune signal to limit self-damage caused by interferon responses [7]. Resolution of the inter-
feron response fails in the AGS patient; the inflammation is chronic and fails to correctly
resolve.
Innate Immune Sensors Read Other Epitranscriptome
Modifications
Data from the Weissman group has demonstrated that in vitro transcribed RNA containing
various modified nucleotides such as m5C, m6A, m5U, pseudouridine, or 20-O-methylated
nucleotides dampen the innate immune response when transfected into mammalian dendritic
cells, whereas RNA that is unmodified will stimulate it [54–56]. The responses observed are
likely to involve RLR as well as TLR sensors.
In the case of inosine effects on RLRs, the inosine–uracil (I-U) wobble base pair weakens
dsRNA base pairing and several I-U base pairs together cause dsRNA melting [57]. It is likely
that it is this perturbation of the helical structure by the I-U wobble base pair that is detected
by RLRs [7]. However, many other types of modified bases could also perturb dsRNA structure
sufficiently for innate immune sensors to distinguish self dsRNA from the perfect dsRNA that
is formed directly from virus replication. For instance, m6A also weakens base pairing in
dsRNA even though it does not alter base pairing preferences [58]. 20-O-methylated groups in
the minor groove would also be easy for RLRs to detect, and these are known to prevent innate
immune induction by dsRNA.
Levels of base modifications often change in response to stress or virus infection. Pseudouri-
dine has been found in mRNA in both yeast and mammalian cells in the past year by three
groups [59–61], all using a similar method of treating the RNA with CMC (N-cyclohexyl-N0-
(2-morpholinoethyl)-carbodiimide metho-p-toluenesulphonate) a chemical that forms a stable
interaction with pseudouridine [62]. When this RNA is subsequently used for cDNA synthesis,
reverse transcriptase will terminate when it encounters the artificial base derivative. When a
stress is applied to cells, such as heat shock of the yeast cells or serum starvation of the mam-
malian cells, this generally increases the level of pseudouridine; however, the biological func-
tion of this stress-induced increase in pseudouridine in mRNA is unclear [63].
Base modification is important in the conflict between virus and host because viruses can
benefit from evading host innate immune responses if they can capture some modifications.
Thus, m6A occurs in some viral RNA at a higher level than would be predicted from a random
occurrence; for example, Rous sarcoma viral mRNA has seven m6A sites, whereas SV40 has
more than ten [64]: it has been shown that TLR 3 is not activated when m6A is present in RNA
[56].
Helm and co-workers have demonstrated that stimulation of the innate immune receptor
TLR7, by tRNA purified from Escherichia coli but not by tRNA from human cells in PBMCs
[65], is due to at least three different modifications on the human tRNAs—two of which are
methylations of ribose 20hydroxyls on tRNA guanosines 18 and 34. These naturally occurring
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modifications in native tRNA not only prevent stimulation of TLR7 by the modified tRNA but
also appear to antagonize TLR7 signalling to suppress immunostimulation by unmodified test
tRNAs, similar to the inhibitory effect of inosine in dsRNA on the activation of RLRs.
Conflicts between self and non-self nucleic acids are much older than the animal innate
immune systems [66], and tRNA modifications may also affect these conflicts. For instance,
the γ-toxin from Kluyveromyces lactis cleaves tRNAsGlu/Gln/Lys from Saccharomyces cerevisiae
on the 30 side of an anticodon base that is modified. The γ-toxin recognizes the cleavage sites
due to the 5-methoxycarbonylmethyl-2-thiouridine wobble base modification present on these
tRNAs in S. cerevisiae but not in K. lactis [67–69].
Recent Advances
Some modified bases lead to particular patterns of misincorporation at the modified base posi-
tion in standard RNA-Seq and indications of RNA modification events can be obtained from
existing RNA sequence databases [70]. New RNA-Seq protocols identify modified sites by
cloning cDNAs synthesised using lower nucleotide concentrations and more discriminating
reverse transcriptases [71] that give increased misincorporation and termination. Also, more
detailed examinations of modified base effects on RLRs are beginning to be investigated [72].
However, considering the abundance and variety of modification in RNA, it will take the devel-
opment of new technology before one can be confident that the encoded RNA is truly being
sequenced.
Conclusion
As Albert Einstein once said, “Fundamental ideas of science are essentially simple.” The use of
host RNA modification to distinguish between host and parasite nucleic acids is reminiscent of
the restriction and modification that occurs in bacterial DNA. With the plethora of modifica-
tions in RNA, it’s easy to envisage these would generate a unique bar code that would be spe-
cies-specific, allowing intricate “self”-“non-self” discrimination.
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